Stakeholder Insight: Breast Cancer (hormone Receptor-negative) - Triple-negative Breast Cancer Offe

Share:    

Introduction

Introduction

While some triple-negative breast cancer (TNBC) patients now have an additional treatment option in the form of Avastin, unmet need remains high. Similarly, despite the availability of Herceptin and Tykerb there is also considerable pipeline activity in HER-2-positive breast cancer. At the same time, there is uncertainty over the optimal way of using Herceptin and Tykerb in this patient subset.

Features and benefits

Share:    
Analysis of the hormone receptor-negative breast cancer market based on a survey of 180 specialists, supported by opinion leader interviews

Epidemiological forecasts of breast cancer incidence and prevalence for the period 201019 in the seven major pharmaceutical markets

Segmentation of incident cases by age group, menopausal status, stage of disease and subtype

In-depth analysis of treatment patterns and regimens prescribed for TNBC and HER-2-positive breast cancer by line of therapy and disease stage

Highlights

Herceptin (trastuzumab; Roche/Chugai) has established a formidable position in the HER-2-positive breast cancer market. At relapse, retreatment with an alternative Herceptin-based regimen is favored over switching to Tykerb (lapatinib; GlaxoSmithKline), reflecting the lack of clinical data showing that switching to Tykerb is beneficial.

Avastin (bevacizumab; Roche/Chugai) has captured considerable market share in first-line metastatic TNBC in the US; loss of this indication would therefore have a large impact on sales. Avastin is also vulnerable to competition from new market entrants (e.g. Sanofi Aventiss iniparib), even if it retains its breast cancer indication.

The popularity of Xeloda (capecitabine; Roche/Chugai) shows that side-effect profile is an important driver of prescribing behavior in metastatic TNBC beyond the first-line of therapy. It is therefore critical that new market entrants in this setting are well tolerated if they are to achieve extensive uptake.

Your key questions answered

Validate new product forecasting based on epidemiology, patient segmentation and treatment rates, and the likely rate of uptake for new products

Understand prescribing trends and identify key factors that influence treatment choices in defined breast cancer populations

Enhance commercial positioning by increasing understanding of current dynamics within the breast cancer market

Table of Contents :

Overview 1

Catalyst 1

Summary 1

About Datamonitor Healthcare 3

About the Oncology pharmaceutical analysis team 3

Executive Summary 5

Scope of the analysis 5

Datamonitor insight into the hormone receptor-negative breast cancer market 5

Contributing experts 7

Related reports 7

Upcoming related reports 7

1. Introduction and Scope 10

Coverage of the Stakeholder Insight Survey 10

2. Epidemiology 11

Introduction and background 11

Key points 11

Disease definition and diagnosis criteria 12

Global variation and historical trends 12

Risk factors 15

Epidemiologic forecasting of breast cancer 17

Description of methods 21

Epidemiologic Forecast Results 23

Discussion 30

Conclusions 32

3. Disease overview 33

Introduction 33

Patient segmentation 35

4. Treatment options 39

Introduction 39

5. Treatment Trends: Stage IIII 45

Triple-negative breast cancer 45

HER-2-positive breast cancer 59

6. Treatment Trends: Stage IV and Relapse 80

Triple-negative breast cancer 80

HER-2-positive breast cancer 113

7. Future Treatment 144

Late-phase pipeline products overview 144

Future treatment scenarios 196

BIBLIOGRAPHY 201

Chapter 2. Epidemiology 201

Chapter 3. Disease Overview 207

Chapter 4. Treatment Options 209

Chapter 5. Treatment Trends: Stage IIII Breast Cancer 211

Chapter 6. Treatment Trends: Stage IV and Relapsed Breast Cancer 212

Chapter 7. Future Treatment 214

APPENDIX A 219

Abbreviations 219

Physician research methodology 219

Physician sample breakdown 220

Contributing experts 221

APPENDIX B 222

The survey questionnaire 222

Datamonitor consulting 276
Share:    

Disclaimer 277

For some-more information, Great fully visit:

http://www.aarkstore.com/reports/Stakeholder-Insight-Breast-Cancer-Hormone-Receptor-Negative-Triple-negative-breast-cancer-offers-a-significant-opportunity-to-new-market-entrants-while-Herceptin-dominates-the-HER-2-positive-market-80660.html

by: Aarkstore Enterprise

POST COMMENT

Jaipur Travel Best Choice For Your Holiday Golden Triangle Tour Five Financial Products For Your Christmas Shopping The American Dream is no More Overnight Trip To Cairo From Alexandria Port, Alexandria Shore Excursions Holiday Inn Aylesbury Origins Of The Native American Pow Wow Running Baggage - A Travelers' Delight Ways To Get Paid Completing Surveys In Australia Handicapped Vans take the Burden out of Traveling Conduct A Comprehensive Credit Card Comparison To Identify The Most Beneficial Deal Festival Tickets: Overcoming Past Failure How To Retool Your Thinking During The Holiday Season